...
 Why us?  Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

 Author  Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making. Authored and medically reviewed by Dr Farzana Khan.

MD MRCGP DFFP
Was this answer helpful?
Rate Dr Farzana's explanation
faq Vaginal Laxity (postnatalmenopause support)

Can HA fillers improve cushioning but not “tighten” the vagina?

Yes—superficial hyaluronic-acid (HA) injectables can add hydration and a gentle cushion at the entrance (vestibule) and lower vaginal wall, easing friction, sting and micro-tears. They do not surgically “tighten” deeper support tissues, correct prolapse or replace pelvic floor training. Think of them as a comfort layer alongside foundations: moisturiser/lubricant, local oestrogen (if acceptable), and supervised pelvic floor rehab. Educational only. Results vary. Not a cure.

Clinical Context

Likely to benefit. Postnatal or peri-/post-menopausal women with focal vestibular sting, recurrent “paper-cut” splits, or early-penetration soreness despite good lubrication—especially where GSM is present and pelvic floor endurance is reasonable. HA may provide a gentle cushion that reduces friction so training and intimacy are easier.

Less suitable right now. Pregnancy; active infection; fever or foul discharge; new post-menopausal bleeding; recent pelvic/perineal surgery without clearance; suspected prolapse beyond the introitus; pain-dominant/overactive pelvic floor (needs down-training and psychosexual support first); clear scar malposition (consider scar-aware therapy and, occasionally, surgical opinion).

Next steps. Continue a supervised 12-week pelvic floor block; schedule a vaginal moisturiser 2–4 nights weekly; use a generous, compatible lubricant (water-based for versatility/condoms; silicone-based for longest glide; avoid oil with latex); note wins (fewer micro-tears, easier speculum/tampon use) to decide if HA is worth adding.

Evidence-Based Approaches

NHS, patient-friendly foundations: Practical guidance on pelvic floor training and vaginal dryness self-care: NHS pelvic floor exercises; NHS – vaginal dryness.

NICE menopause guideline (NG23): Recommends vaginal moisturisers/lubricants and considering low-dose local vaginal oestrogen when symptoms affect quality of life; procedural/injectable options are not first-line for GSM or “laxity”. NICE NG23.

NICE urinary incontinence/prolapse (NG123): Emphasises supervised pelvic floor muscle training as first-line with clear criteria for escalation—principles that underpin stepwise decisions before any adjunct. NICE NG123.

Cochrane reviews: Systematic reviews consistently support pelvic floor muscle training for continence/pelvic floor symptoms—hence foundations before injectables or devices. Cochrane Library – PFMT reviews.

Regulatory perspective (UK): Selection should consider product intended use and appropriate UKCA/CE marking; unexpected effects can be reported via national schemes. MHRA – medical devices.